The Evolution of RANO Criteria: Improving Accuracy in Brain Tumor Assessment
Webinar
The evolution of response assessment for neuro-oncology (RANO) has allowed for development of refined criterion with the goal of increasing accuracy in the longitudinal assessment of brain neoplasms.
Subspecialty reads including RANO-HGG (high-grade glioma), iRANO (immunotherapy RANO) and RANO-BM (brain metastases) have become increasingly utilized in evaluating treatment response in their respective clinical settings. These criteria have helped address some of the response assessment challenges in the clinical trial setting in this patient population, especially with the continued development of novel therapeutic agents.
Join Dr. Pareen Mehta as he discusses:
- The evolution of RANO criteria for brain neoplasms
- RANO-HGG, iRANO and RANO-BM criteria
- The challenges of brain tumor assessment and the importance of neuroradiology input in clinical trial design